Sporothrix schenckii and Sporotrichosis

Mônica Bastos de Lima Barros1* Rodrigo de Almeida Paes,2 and Armando Oliveira Schubach2

National School of Public Health1 and Evandro Chagas Clinical Research Institute,2 Fiocruz, Rio de Janeiro, Brazil

INTRODUCTION ..............................................................................................................................................633

HISTORY ...........................................................................................................................................................634

TAXONOMIC STUDIES .................................................................................................................................634

SPOROTrix CELL BIOLOGY ................................................................................................................................635

Morphology .......................................................................................................................................................635

Cell Wall ..........................................................................................................................................................636

S. SCHENCKII GENETIC MATERIAL .............................................................................................................636

S. SCHENCKII PHYSIOLOGY ..........................................................................................................................636

S. SCHENCKII ECOLOGY ...............................................................................................................................637

PUTATIVE S. SCHENCKII VIRULENCE FACTORS .......................................................................................637

Thermotolerance .............................................................................................................................................638

Melanin ............................................................................................................................................................638

Adhesion ..........................................................................................................................................................638

Ergosterol Peroxide .........................................................................................................................................639

Proteins Related to Virulence .......................................................................................................................639

IMMUNE RESPONSE IN SPOROTROCHOSIS ..............................................................................................639

Innate Response ............................................................................................................................................639

Cellular Response .........................................................................................................................................639

Humoral Response .........................................................................................................................................640

SPOROTROCHOSIS DIAGNOSIS ....................................................................................................................640

Direct Examination .......................................................................................................................................640

Histopathological Examination ...................................................................................................................641

Culture .............................................................................................................................................................641

Molecular Detection ......................................................................................................................................641

Sporotrichin Skin Test .....................................................................................................................................642

Antibody Detection .........................................................................................................................................642

EPIDEMIOLOGY ..............................................................................................................................................643

Geographic Distribution ...............................................................................................................................643

Distribution by Age and Gender ................................................................................................................643

Transmission and Sources of Infection ......................................................................................................643

Zoonotic Transmission ..................................................................................................................................644

PATHOGENESIS AND CLINICAL FORMS .................................................................................................645

Human Disease ..............................................................................................................................................645

Cutaneous forms ..........................................................................................................................................645

Mucosal form ..................................................................................................................................................646

Extracutaneous form .....................................................................................................................................646

Associated signs and symptoms ..................................................................................................................646

Differential diagnosis .....................................................................................................................................646

Feline Disease ................................................................................................................................................646

TREATMENT ...................................................................................................................................................647

Antifungal Susceptibility Tests ...................................................................................................................647

PREVENTION ...............................................................................................................................................649

ACKNOWLEDGMENTS ...............................................................................................................................649

REFERENCES ..................................................................................................................................................649

INTRODUCTION

Sporotrichosis, caused by the dimorphic fungus Sporothrix schenckii, is currently distributed throughout the world, especially in tropical and subtropical zones. Infection generally occurs by traumatic inoculation of soil, plants, and organic

* Corresponding author. Mailing address: Fundação Oswaldo Cruz/ Fiocruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro CEP 22045-900, Brazil. Phone: 55 21 2598 2518. Fax: 55 21 3415 2086. E-mail: mblbarros@fiocruz.br.
systemic disease. Several factors, such as inoculum load, immune status of the host, virulence of the inoculated strain, and depth of traumatic inoculation, influence the different clinical forms of sporotrichosis. The gold standard for sporotrichosis detection is culture; however, serological, histopathological, and molecular approaches have been recently adopted as auxiliary tools for the diagnosis of this mycotic infection.

**HISTORY**

*Sporothrix schenckii* was isolated for the first time in 1896 by Benjamin Schenck, a medical student at the Johns Hopkins Hospital in Baltimore, MD, from a 36-year-old male patient presenting lesions on the right hand and arm. This isolate, from the patient abscess, was then studied by the mycologist Erwin Smith, who concluded that the fungus belonged to the genus *Sporotrichum* (217). Previously, Linck in 1809 and Lutz in 1889 referred to some possible sporotrichosis cases, but the isolation of the fungus by these authors for case definitions was not possible (126). The second undeniable sporotrichosis case was described in 1900 by Hektoen and Perkins, also in the United States (Chicago, IL). This was the case of a boy who suffered an injury with a hammer hitting his finger, with the lesion presenting spontaneous regression. These investigators gave the sporotrichosis agent its current denomination, *Sporothrix schenckii* (95). Later, this fungus was erroneously included in the genus *Sporotrichum*, which comprises basidiomycetous fungi which are neither dimorphic nor pathogenic for humans or other animals (216). This erroneous nomenclature remained until 1962, when Carmichael recognized differences in the conidiations of members of the genus *Sporotrichum* and isolates from sporotrichosis cases (37).

In 1903, Sabouraud suggested to Beurm and Gougerot the use of potassium iodide for the treatment of sporotrichosis, which was a common disease in France during the beginning of the 20th century (126). This has hitherto been a satisfactory therapy for sporotrichosis, although no randomized, double-blind, placebo-controlled trials have ever been conducted (267).

The first reported case of natural animal infection was described in 1907 by Lutz and Splendore in rats from Brazil (141). The possibility of human infection by bites from these rats was considered (186). Also in Brazil, in 1908, Splendore reported the detection of asteroid bodies around *Sporothrix* yeast cells, which offer a very useful tool for sporotrichosis diagnosis in histological examinations (126, 196).

**TAXONOMIC STUDIES**

*Sporothrix schenckii* belongs to the kingdom Fungi and is a eukaryotic organism that is without mobility and heterotrophic and presents chitin on its cell wall. For several years, this fungus was included in division *Eucomicota*, subdivision *Deuteromycotina*, class *Hyphomycetes*, order *Moniliiales*, and family *Moniliaceae* (128). After a substantial fungal taxonomy revision by Guarro and coworkers, this fungus was characterized in division *Ascomycota*, class *Pyrenomycetes*, order *Ophiostomatales*, and family *Ophiostomataceae* (84).

The sexual form of *S. schenckii* is as yet unknown. However, there is substantial molecular evidence that this fungus undergoes recombination in nature (163). Nevertheless, some studies imply that *S. schenckii* in an ascomycete, since it presents a simple septum, with Woronin bodies (237) and three chitin synthase genes (44).

Molecular analyses of the 18S region of the ribosomal DNA indicate that the sexual form of *S. schenckii* could be *Ophiostoma stenoceras* (22). On the other hand, morphological and physiological studies exhibit consistent differences between these two species. *O. stenoceras* is unable to produce dematiaceous conidia, as does *S. schenckii*. Also, *S. schenckii* does not produce peritheciun on malt, rice, or potato media, as is observed for isolates of *O. stenoceras* (60, 181). Differences are also apparent when these species are inoculated in mice. *S. schenckii* can be found in several tissues from all infected mice after intravenous inoculation, and *O. stenoceras* is detected in certain organs from some infected animals (59). These observations lead to the conclusion that the *O. stenoceras* anamorph and *S. schenckii* are different species. Meanwhile, other molecular studies (56, 97), together with work by Berbee and Taylor (22), reinforce that the *S. schenckii* teleomorph is classified in the genus *Ophiostoma*. Berbee and Taylor highlight that *S. schenckii* belongs to the pyrenomycete lineage, lacking forcible ascospore discharge (22).

Recently, Marimon and coworkers (150), on the basis of phenotypic and genotypic analyses, suggested that *S. schenckii* should not be considered the only species that causes sporotrichosis, and based on macroscopic characteristics, sucrose and raffinose assimilation, ability to grow at 37°C, and the nuclear calmodulin gene sequence, they described four new species in the *Sporothrix* complex: (i) *S. globosa*, a fungus distributed worldwide (145, 180); (ii) *S. brasiliensis*, the species related to the zoonotic epidemic of sporotrichosis in Rio de Janeiro, Brazil (150, 179); (iii) *S. mexicana*, limited to Mexico (150); and (iv) *S. luriei*, formerly *S. schenckii* var. *luriei* (151), differing from *S. schenckii* mainly in the tissue form by the production of large, often septate budding cells unable to assimilate creatinine or creatine (53). On the other hand, other authors support its separation by rRNA internal transcribed spacer (ITS) sequence data (54). Another species, *S. cyaneo-sens* has been isolated from blood and skin samples from human patients, but pathogenicity studies conclude that, although this fungus can grow at 37°C, it is avirulent (233). Figure 1 presents a key to differentiate species within the *S. schenckii* complex (151).

Recently, de Meyer and collaborators (56) described three other environmental *Sporothrix* species, *S. stylites*, *S. humicola*, and *S. lignivora*. The first two species differ from *S. schenckii* by the inability to produce melanized conidia and the consequent nondarkening of colonies with age. *S. lignivora* has distinctive conidia that do not match in size and shape those of other *Sporothrix* or *Ophiostoma* species. It is interesting to note that isolates classified as *S. humicola* were previously referred to as environmental isolates of *S. schenckii*. In their study, the authors concluded that β-tubulin sequence analysis is strongly recommended for taxonomic studies of *Sporothrix* species isolated from the environment.
**SPOROTHRIX CELL BIOLOGY**

**Morphology**

*Sporothrix schenckii* is a dimorphic fungus. In its saprophytic stage or when cultured at 25°C, it assumes a filamentous form, composed of hyaline, septate hyphae 1 to 2 μm wide, with conidiogenous cells arising from undifferentiated hyphae forming conidia in groups on small, clustered denticles. These one-celled conidia are tear shaped to clavate (53) and do not yield chains (233). Often, hyaline or brown thick-walled conidia arise beside the hyphae. The dark cell walls of the conidia distinguish *S. schenckii* from other, nonpathogenic *Sporothrix* species (56, 242). Macroscopically, filamentous colonies in media such as malt extract agar or potato dextrose agar (Fig. 2) are often smooth and wrinkled, white to creamy at first and then turning brown to black after a few days (126, 170, 196). Some strains, however, have the ability to form dark colonies from the beginning of growth (5). The *S. schenckii* colonies never become cottony or floccose (126).

This fungus is evident in both human and animal tissues as budding yeasts. Yeastlike cells can be observed in various sizes and shapes. They may be round to oval, with 2- to 6-μm diameters, and usually have elongated, cigar-shaped buds on a narrow base. Macroscopically, yeast colonies (Fig. 2) are smooth, tan, or cream colored (130). Some molecular aspects implicated in proliferation and maintenance of this morphological form of *S. schenckii* involve calcium/calmodulin-dependent protein kinases (260) and a signaling pathway involving the interaction between a cytosolic phospholipase and protein G. Studies have proven that this pathway is necessary for the reentry of *S. schenckii* yeast cells into the budding cycle, suggesting its function in the control of dimorphism in this fungus and for the maintenance of the yeast form (259).

The transition from mold to yeast form in *S. schenckii* can be attained by culturing mycelia or conidia on rich culture media such as brain heart infusion agar at 35 to 37°C (170). Some strains, especially those related to the *S. globosa* species, may require lower conversion temperatures, since they do not grow well at 37°C (150). Although rich media are required for the mycelium-to-yeast transition, *S. schenckii* yeast cells can be maintained at 37°C in other media, such as Sabouraud dextrose agar. This transition process also occurs after patients are infected with filamentous *S. schenckii*. Morphological transformation at the ultrastructural level occurs by direct formation of budlike structures at the tips and along the hyphae together with oidal cell formation after septation of the hyphae, without conspicuous alterations of the cytoplasmic content of parent mycelial cell. There is no direct budding of yeast from conidiospores (77).

![FIG. 1. Identification key for Sporothrix species of clinical interest, based on morphological and phenotypic tests described by Marimon and collaborators (152). PDA, potato dextrose agar; CMA, corn meal agar.](http://cmr.asm.org/)

![FIG. 2. Cultures of pus from lesions of *S. schenckii*-infected patients. Most strains become visible after 4 days of growth on Sabouraud dextrose agar, presenting no visible dark pigment at this stage (tube at left), whereas others are melanized since the beginning of growth (tube at center). When transferred to brain heart infusion agar and cultured at 37°C, strains undergo dimorphism, presenting creamy white to tan yeast colonies after 7 days of growth (tube at right).](http://cmr.asm.org/)
The beginning of the yeast-to-mycelium transition in *S. schenckii* is a process regulated by calcium, which induces both RNA and protein synthesis on the yeast cell (199). A prerequisite for this transition process is a nuclear division; afterwards, a germ tube is originated from the parental yeast cell and a septum is formed at mother cell-germ tube formation (25). It is interesting to note that yeast cells can be maintained at 25°C if cultured in liquid media with glucose and with the pH around 7.2 (195, 260).

**Cell Wall**

Like other fungi, *S. schenckii* has a cell wall surrounding the plasma membrane in both the mycelial and yeast forms. There are characteristic differences in cell wall thickness between conidia, yeast forms, and filaments, as well variations in plasma membrane invaginations among these three morphological forms of the fungus. It has been shown by freeze fracturing studies that in conidia invaginations are short and abundant and in yeast forms they are scarce and longer, while the plasma membrane of the *S. schenckii* hyphae is smooth, without invaginations (244).

The fungal cell wall is rigid as well as complex, and recently it has been shown that *S. schenckii* produces vesicles that are probably related to the transfer of periplasmic molecules and pigment-like structures from the plasma membrane to the extracellular space, since in contrast to the case for prokaryotic organisms, in eukaryotic cells there is vesicular traffic of molecules to the plasma membrane (3, 197).

The chemical structures of fungal cell wall polysaccharides and glycoproteins have been studied basically because of the knowledge of the antigenic structures of human pathogens (193). A peptide-rhamnomannan was isolated from the yeast *S. schenckii* cell wall, where there were the polysaccharides α-mannose (50%) and α-rhamnose (33%), small amounts of galactose (1%), and about 16% peptides (138). Comparative studies of mycelial and yeast *S. schenckii* cell walls showed little difference in the glycosidic components. The cell wall composition of the mycelial phase included large amounts of lipids and protein and a lower concentration of mannose (193). The cell wall composition in *S. schenckii* conidial cells can also be affected by the time of culture, with a decrease in the rhamnose molar ratio and an increase in the mannose molar ratio (67).

The yeast cell wall of *S. schenckii* also contain granules of melanin (250) and proteins involved in adherence (135, 206), which contribute to fungal virulence. Of particular interest is a glycoprotein of 70 kDa isolated from the cell wall of the *S. schenckii* yeast phase. The purified glycopeptide has a pI of 4.1, and about 5.7% of its molecular mass is composed of N-linked glycans, with no evidence for O-linked oligosaccharides in this molecule. This glycoprotein has a uniform distribution on the fungal cell surface and participates in adhesion to the dermal extracellular matrix (206).

**S. SCHENCKII GENETIC MATERIAL**

Little is known about the *S. schenckii* genomic composition because this fungus is not amenable to genetic analysis based on meiotic segregation (256). Studies on the genomic DNA base composition rendered an average guanine and cytosine content of about 54.7 mol%, with the DNA showing a low degree of hybridization with *O. stenoceras* DNA, supporting the supposition that this fungus does not represent the sexual state of *S. schenckii*. However, 75% hybridization was observed with *Ophistoma minus* DNA (159). More recently, Tateishi and coworkers (249), karyotyping eight strains isolated from patients in Japan, concluded that *S. schenckii* possesses six to eight chromosomes of 460 to 6,200 kb, with a total genome size of approximately 28 Mbp. Another study with strains from a different geographical origin predicted a 45-Mbp genome size for *S. schenckii* (256). Perhaps these differences are related to either the different species recently described (150) or to underestimations in the methods adopted for genome size determination. Also, it has been reported that *S. schenckii* is a diploid organism, bearing around 50 fg DNA per cell, in both the filamentous and yeast phases. On the other hand, aneuploidy, a state in which most of the chromosomes are disomic, cannot be excluded (256). It is interesting to note that diploidy is essential for thermal dimorphism in *Cryptococcus neoformans*, and similarities in life cycle between this fungus and other dimorphic fungi, including *S. schenckii*, may occur (232).

Studies on identification, typing, and epidemiology of sporotrichosis are usually based on mitochondrial DNA (mtDNA) analysis of restriction length polymorphisms (RFLP) with the restriction enzyme HaeIII. Initially, 24 mtDNA types were cited (136), and more recently types 25 to 30 (168) and 31 to 32 (103) were introduced. These analyses have been adopted in several studies with *S. schenckii* strains from different geographical origins and also environmental isolates (13, 103, 104, 243, 266).

**S. SCHENCKII PHYSIOLOGY**

Even though sporotrichosis is a disease distributed worldwide, there are only a few studies regarding the physiological characteristics of its agent. In general, the optimal temperature for *S. schenckii* growth is around 30 to 37°C, with growth of all strains being impeded at 40°C (79, 150). Although *S. schenckii* is able to grow at 35 to 37°C, some growth inhibition is observed compared to that at 28°C. Moreover, this inhibition appears to be geographically related (163).

Several carbohydrates can be assimilated by *S. schenckii*, such as glucose, fructose, mannose, and cellobiose (79, 200). However, there is some variability in assimilation of sucrose, arabinose, starch, raffinose, and ribitol (79, 150). Starch assimilation is also affected by fungal preservation under some storage methodologies, such as the Castellani method (160). The carbohydrate concentration available during *S. schenckii* growth modulates melanin synthesis by this fungus (Fig. 3), enhancing pigment formation in a glucose concentration-dependent manner (5). This fungus is not able to ferment any carbohydrate (53).

Some physiological differences between the two different *S. schenckii* morphologies may be observed. Mycelial-phase *S. schenckii* can grow well at pHs of around 3.0 to 11.5, but yeast cells can grow only within the pH range of 3.0 to 8.5. The yeast phase is also more osmotolerant (30%) than the mycelial phase (20%), as is true for halophilia. The mycelial phase withstands growth in 7% NaCl, but the yeast-phase *S. schenckii* can grow well in 11% NaCl (79).
S. schenckii is able to split urea (79, 150, 233), perform reductive iron acquisition with secreted extracellular enzymes (270), and tolerate cycloheximide at 0.25% (150). Thiamine is required for fungal growth (60, 101).

S. SCHENCKII ECOLOGY

S. schenckii often enters the host through traumatic implantation (126, 129, 170, 196). In nature, the fungus has been found to live as a saprophyte on living and decaying vegetation, animal excreta, and soil (118, 126, 156, 162). Organic material in soil is fundamental for mycelium development. The fungus thrives in soil plentiful in cellulose, with a pH range from 3.5 to 9.4 and a temperature of 31°C (177). The relative humidity cannot be below 92% (126).

It has been proposed that the armadillo Dasypus septemcinctus may be a reservoir of S. schenckii, since armadillo hunting was reported by several patients with sporotrichosis in Uruguay (143). In fact, this armadillo harbors S. schenckii in neither its intestine nor its epidermis, but the fungus can be found on the dry grass used by these animals for nesting (126). Here we find an apparent incongruity between the organisms needing high humidity for growth (126) yet being found on dry grass of armadillo nests. Probably these differences are geographically related, like growth inhibition at high temperatures (163). Moreover, we cannot discard the hypothesis that different species within the S. schenckii complex (150, 151) have different humidity requirements for growth.

There is another armadillo species, Dasypus novemcinctus, which is susceptible to systemic, fatal sporotrichosis (111, 264). Other animals related to S. schenckii transmission are parrots, rodents, cats, dogs, squirrels, horses, and birds (126, 212). Moreover, S. schenckii was also isolated from aquatic animals, primarily fish and dolphins (91, 164), as well as from insects that had been in direct contact with the fungus (126). Some authors have reported sporotrichosis cases due to mosquito bites (129).

It has been confirmed that S. schenckii is associated with plants. Sphagnum moss, rose thorns, and hay are especially recognized to harbor this pathogenic fungus (64, 71, 156). However, S. schenckii does not have the potential to be a plant pathogen, probably because extracts from several plants have antifungal activity against S. schenckii (81, 153, 154, 213). In fact, it has been described that when S. schenckii is inoculated in living or dead sphagnum moss, the fungal cell population proliferates in the moist dead plants but not in live moss (271), suggesting that plants have some mechanism to control S. schenckii overgrowth.

There has been some reports about S. schenckii isolation from food (1, 117). Nevertheless, this fungus does not appear to have the potential to cause food-borne infection (116).

There are some reports on the isolation of S. schenckii from environmental sources. Methods include direct isolation of the fungus by plating the supernatants of samples suspended in water or physiological saline solution with antibiotics in Mycosel agar medium or by inoculation of this suspension in susceptible mice, such as BALB/c, with further culture of spleens, livers, and lungs of the infected animals (60, 162). Direct isolation appears to be more effective to obtain S. schenckii from environmental samples. However, colonies obtained after mouse inoculation have been free of microbial contamination (162).

PUTATIVE S. SCHENCKII VIRULENCE FACTORS

We can define a virulence factor as a feature of a microorganism that allows or enhances microbial growth in the host. To study and characterize these factors, is necessary compare the microbe-host interactions of an isolate that expresses the suspected factor and a mutant isolate that has lost the ability to express it, which can be attained by induced mutagenesis through molecular strategies. If differences in the infections caused by these different isolates are noted, it is imperative to make the mutant isolate recover the ability to express the studied factor and check whether or not the organism then regains the capacity to cause infection similar to that of the parental wild-type strain (100).

Discovery of the origin of microbial virulence has been the main goal of several studies. In general, the most accepted theory is that with microbial interactions with other organisms present in the natural habitat of the pathogen, the microorganisms acquire survival strategies tending to a higher virulence when they accidentally find an animal host. For instance, these microorganisms, in the mammalian host, usually have the ability to form biofilms and mechanisms to acquire iron and produce proteolytic enzymes that will lead to higher virulence (40).

Regarding this theory, Steenbergen and coworkers (240) suggested that the origin of virulence in S. schenckii should be related to the intermicrobial interactions in its environment. The authors demonstrated that when ingested by Acanthamoeba castellanii, a soil amoeba, S. schenckii yeast cells are able to survive within the protozoan, kill it, and use it as nutrient. This behavior is not shared by pathogenic fungi that do not have the soil as habitat, such as Candida albicans, or by fungi that are not primarily pathogenic, such as Saccharomyces cerevisiae. On the other hand, other dimorphic fungal patho-

FIG. 3. Glucose concentration-dependent increase of melanin synthesis. The concentration of glucose (% wt/vol) in each culture is indicated by the numbers on the agar plates. S. brasiliensis strain 17307, grown at 22°C (A), and S. schenckii strain 23250, grown at 37°C (B), are representative isolates showing enhancement of melanization with increasing glucose amounts.
gens, such as *Histoplasma capsulatum* and *Blastomyces dermatitidis* (240) as well as *Cryptococcus gattii*, a highly virulent yeast pathogen (148), have the same behavior as *S. schenckii* when in contact with *A. castellanii*.

Little is known about *S. schenckii* virulence factors due to the lack of studies in this field, in part because *S. schenckii* is not responsive to genetic analysis. However, some putative virulence factors have appeared from some investigations.

**Thermotolerance**

One of the putative *S. schenckii* virulence factors, which is also a virulence factor of other pathogenic fungi, is thermotolerance (40). In fact, isolates able to grow at 35°C but not at 37°C are incapable of causing lymphatic sporotrichosis and produce fixed cutaneous lesions instead. The fungi isolated from lymphatic, disseminated and extracutaneous lesions show tolerance and growth at 37°C (126). Results from a more recent study demonstrate that *S. schenckii* isolates from Colombia, where most patients are affected with fixed cutaneous sporotrichosis, exhibit high growth inhibition at 35 and 37°C, in contrast to isolates from Mexico and Guatemala, where lymphatic sporotrichosis prevails (163). In an *in vivo* mouse assay, it has been shown that if the mice have their feet warmed in cages with heat on the floor, progression of sporotrichosis is reduced compared to that in control infected mice maintained in regular cages. Isolates from pulmonary lesions, however, replicate regularly in both groups of mice (246).

**Melanin**

Both morphological stages of *S. schenckii* have the ability to synthesize melanin. This is an insoluble compound highly related to virulence in several fungi (106). Melanin production in *S. schenckii* dematiaceous conidia occurs through the 1,8-dihydroxynaphthalene (DHN) pentaketide pathway (202). Microscopically, only the mycelial phase of the fungus is melanized. However, melanin production in yeast cells was demonstrated *in vitro* during infection (171). Recently, it has been demonstrated that *S. schenckii* can also produce melanin using phenolic compounds such as 3,4-dihydroxy-L-phenylalanine (L-DOPA) as a substrate both in filamentous and yeast forms (5). It is interesting to note that only conidia can be melanized by the DHN pathway, but if L-DOPA is present, hyphae can be melanized as well (Fig. 4).

Since *S. schenckii* is a soil-accommodated fungus that does not require host parasitism to complete its life cycle, fungal melanization must be also important against unfavorable environmental conditions, since mycelium is the fungal form encountered in nature (171).

*In vitro* studies indicate that melanization in *S. schenckii* is controlled by several factors, such as temperature, pH, and nutrient conditions (5). Moreover, similar culture media from different suppliers can yield differences in melanization within a single *S. schenckii* strain (250). It has been shown that conidial melanization enhances *S. schenckii* resistance to macrophage phagocytosis, allowing the first steps of infection, since these structures usually are the fungal infective particles (202). Corroborating this hypothesis, it has been demonstrated by molecular typing of an *S. schenckii* strain isolated from a laboratory worker who had handled a pigmented strain and an albino strain of *S. schenckii* that the isolate from the patient had the same genotypic profile as the dematiaceous strain (48).

Melanization also has a role in the pathogenesis of cutaneous sporotrichosis, since pigmented isolates had a greater invasive ability than the albino mutant strain in an experimental rat model of sporotrichosis. The albino strain also was restricted to the core of the granuloma. In addition, the melanized strain promoted the formation of multifocal granulomas (145).

Some *S. schenckii* melanization *in vivo* has been previously described, such as a weak brown halo on the yeast *S. schenckii* cell wall when infected sporotrichosis tissues are stained with Fontana-Masson stain, a technique initially developed to demonstrate melanin in *C. neoformans* (127). This hypothesis has now been confirmed by detection of *Sporothrix* melanin ghosts in tissues from infected animals as well as by detection of antimelanin antibody in sera from patients with sporotrichosis (5, 171). Since melanization decreases the susceptibilities of *H. capsulatum* and *C. neoformans* to amphotericin B and caspofungin (261), melanin pigment in *S. schenckii* may hamper treatment in some sporotrichosis cases, especially in cases of extracutaneous disease or in patients infected with human immunodeficiency virus (HIV) (171). However, there have been no studies confirming this hypothesis.

**Adhesion**

Primary adhesion to endothelial and epithelial cells as well as on extracellular matrix components is essential to an effective invasion of host tissues by pathogens. Both conidia and yeast cells from *S. schenckii* are able to recognize three impor-

---

**FIG. 4.** Melanin ghosts of *S. schenckii* 18782 strain under several culture conditions. (A) Cultures on minimal medium at 25°C yield melanin ghosts only from dematiaceous conidia. (B) When L-DOPA is added to minimal medium, both hyphae and conidia are melanized. (C) Yeast *S. schenckii* cells can also produce melanin in culture medium free of phenolic compounds or when L-DOPA is added. Bars, 10 μm.
tant glycoproteins from the extracellular matrix: fibronectin, laminin, and type II collagen (134, 135). Some studies have demonstrated that the fungus has integrins or adhesin lectin-like molecules that recognize human fibronectin at several points on the molecule (135). The fibronectin adhesins are located on the surface of yeast cells, and their expression is related to fungal virulence (251). It is also known that these fibronectin receptors are different from laminin receptors (133). These receptors are present on both hyphae and fungal yeasts, although yeasts have a greater ability to bind to the extracellular matrix. The existence of these adhesins would favor adherence to host tissues and fungal dissemination throughout the body (133). Expression of these molecules in S. schenckii is probably related to virulence, since their preferential expression is in the parasitic rather than the saprophytic form of the fungus. Recently a 70-kDa glycoprotein from an S. schenckii isolate was described, and its participation in adhesion to the dermal extracellular matrix was demonstrated (206).

This fungal pathogen is also able to interact in vitro with human endothelial cells, which can internalize fungal yeast cells without injury or decreased viability. Moreover, the fungus can also cross the intercellular space. Both processes facilitate fungus bloodstream penetration and consequent hematogenous dissemination (69). Transendothelium migration occurs through a paracellular route involving extracellular matrix proteins, in a process mediated by transforming growth factor β1 (TGF-β1) (70). Although the endothelial proteins responsible for this interaction have been characterized, fungal proteins needed for recognition of and adhesion to these cells are unknown, and their part in fungal virulence requires clarification.

**Ergosterol Peroxide**

Sgarbi and coworkers, analyzing lipids from S. schenckii through spectroscopic methods, have identified ergosterol peroxide from S. schenckii yeast cells. This compound can be converted to ergosterol when in contact with an enzyme extract from the fungus. The ergosterol peroxide, found in a pathogenic fungus for the first time in S. schenckii, is formed as a protective mechanism to evade reactive oxygen species during phagocytosis and may also represent a virulence factor. Apparently, however, survival of virulent S. schenckii yeast cells after phagocytosis of polymorphonuclear host cells relies on other detoxification strategies besides the one leading to ergosterol peroxide synthesis (32, 231).

**Proteins Related to Virulence**

Roles of diverse proteins in the virulence of different fungal pathogens have been described. For instance, the *Paracoccidioides brasiliensis* immunodominant antigen, a glycoprotein of 43 kDa, is the molecule responsible for laminin and fibronectin recognition and binding, which increase fungal virulence (158, 262). Calcium binding proteins are important in *H. capsulatum* virulence, enabling acquisition of this ion in environments with calcium limitations (265). A series of virulence-related proteins, such as different adhesins, have been described for *Aspergillus fumigatus*, including a 30-kDa hemolysin containing several proteases that favor pulmonary colonization and destruction of effective humoral molecules and a 350-kDa cathepsin needed for phagocytosis survival (131). However, the function of different S. schenckii proteins in virulence is still unclear. It is believed that acid phosphatases act on fungus-macrophage interactions, although no definitive evidence to support this theory exists (100). Peptido-rhamnomannans of the fungal cell wall cause depression of immune response until the sixth week of infection and may act as a virulence factor (34). An antigenic preparation from the S. schenckii yeast phase shows proteolytic activity against different human IgG subclasses, suggesting that some secreted proteins may interfere with the immune response of the host (204). Due to the lack of information, characterization of S. schenckii proteins and determination of new virulence factors are imperative for a better understanding of sporotrichosis pathogenesis.

**IMMUNE RESPONSE IN SPOROTRICHOSIS**

The virulence of S. schenckii is one of the factors thought to play a role in the development of sporotrichosis (32), but there are discordant results concerning disease evolution in experimental sporotrichosis with S. schenckii clinical isolates from cutaneous and disseminated infection (29, 176), indicating that host immune responses also substantially participate in the progress of sporotrichosis (32).

The immunological mechanisms involved in prevention and control of S. schenckii infections are still not very well understood. However, they probably include both humoral and cellular responses (32, 33, 147), which appear to be triggered by distinct antigens. Surface cell antigens, especially some lipids, inhibit the phagocytosis process, while the humoral response is induced by secreted fungal proteins, the exoantigens, which are not involved in the cellular response (35). The innate immune response also plays a role in the pathogenesis of sporotrichosis (32).

**Innate Response**

A complement system can be activated by S. schenckii, especially the alternate pathway, although classic complement activation cannot be excluded. Complement activation may support fungal yeast cell phagocytosis by C3b component deposition on the fungal cell wall. The membrane attack complex also contribute to fungal cell lysis (230, 255).

Recent studies have emphasized the importance of Toll-like receptor 4 (TLR4) in sporotrichosis. TLR4, also designated CD284, is an important molecule involved in the activation of the innate immune system that, in sporotrichosis, is able to recognize molecules within a lipid extract from the yeast form of the fungus. This interaction leads to the induction of an oxidative burst against the fungus (32).

**Cellular Response**

Acquired immunity against the fungus requires the action of activated macrophages. They can be activated during sporotrichosis by CD4 T lymphocytes, which release gamma interferon (IFN-γ), a strong macrophage activator (247), and by other antigen-presenting cells, establishing a link between innate and
adaptive immune responses (32). Tumor necrosis factor alpha (TNF-\(\alpha\)), a cytokine that acts on activated macrophages to produce nitric oxide (35), an antioxidant product presenting a high cytotoxic effect against \(S.\) schenckii (66), is produced upon incipient and terminal infection, hopefully providing total resolution (147). Although nitric oxide is a fungicidal molecule, this compound may be implicated in immunosuppression in vivo, because high levels of TNF-\(\alpha\) and NO released after yeast dissemination into the tissues lead to the induction of molecules suppressing T cell responses, such as interleukin10 (IL-10), FasL, and CTLA-4. This deleterious effect of NO occurs just upon initial infection, becoming crucial some time after fungal inoculation (68). In fact, TNF-\(\alpha\) production drastically subsides at 4 to 6 weeks after experimental infection, inducing the fungus to reproduce and infect host tissues. The opposite situation occurs 2 months after infection, when the levels of IL-1 and TNF-\(\alpha\) increase, favoring fungal elimination (36).

After the phagocytosis of \(S.\) schenckii conidia and yeast cells, monocytes and macrophages are also strongly induced to produce reactive oxygen species (202). These reactive species, especially superoxide anion and its oxidative reactive metabolites, which are also produced by neutrophils, are involved in fungistatic and fungicidal responses, and their absence is related to a higher lethality in mouse experimental infections (108). Therefore, the Th1 response is of great importance in sporotrichosis pathogenesis, acting as the key factor in controlling fungal infection and with its differential activation leading to varied clinical manifestations of the disease (258). Similar observations on the activation of Th1 cells have led to them being seen as being responsible for different clinical manifestations in other cutaneous infectious diseases, such as leishmaniasis (38).

### Humoral Response

The humoral immune response is driven by IL-4 produced by Th2 cells. In experimental sporotrichosis, IL-4 release is enhanced at 5 to 6 weeks after infection (147), suggesting the participation of the humoral immune response only in the advanced stages of sporotrichosis (32). Antibodies may have some effect on \(S.\) schenckii development, since a monoclonal antibody against a glycolipid antigen is able to hinder \(S.\) schenckii growth and differentiation in vitro (254). A monoclonal antibody against the 70-kDa adhesin is also protective in murine model of sporotrichosis (174). Nonetheless, little is known about antibodies elicited during the course of sporotrichosis. It has been described that mice infected with \(S.\) schenckii are able to produce specific IgG1 and IgG3 antibodies against a 70-kDa fungal protein during experimental infection, with these antibodies perhaps being related to fungal elimination in these organisms (173). During human sporotrichosis, our group has demonstrated the production of IgG, IgM, and IgA antibodies against mycelial-phase \(S.\) schenckii exoantigens. Nevertheless, since patients with different clinical forms of sporotrichosis produce similar amounts of these antibodies, we believe that the humoral immune response against proteins secreted by \(S.\) schenckii does not play a role in sporotrichosis pathogenesis (6).

**SPOROTRICHOSIS DIAGNOSIS**

Sporotrichosis can be diagnosed through a correlation of clinical, epidemiological, and laboratory data. Laboratory analysis for the determination of sporotrichosis includes direct examination of specimens such as tissue biopsy specimens or pus from lesions. In case of disseminated infections, other specimens, such as sputum, urine, blood, and cerebrospinal and synovial fluids, can be analyzed, depending on the affected organs.

### Direct Examination

Direct examination of specimens is usually conducted with 10% potassium hydroxide in order to observe parasite budding yeast cells. These yeasts are small (2 to 6 \(\mu\)m in diameter) and scarce and consequently are difficult to detect upon direct examination of specimens collected from humans. However, when the same test is performed with samples collected from infected cats, due to the high fungal burden in these animals, yeast cells can be easily found, even at a magnification of \(\times400\) (Fig. 5). Fluorescent-antibody staining can help in the observation of yeast forms of \(S.\) schenckii; however, this is not a technique that is readily available in most laboratories (130), especially in underdeveloped countries. When the Gram stain is used on the clinical material, yeast cells appear positively stained, sometimes within giant cells or polymorphonuclear lymphocytes (129). For the detection of \(S.\) schenckii, some authors recommend Giemsa stain after 10 to 15 dilutions of...
pus in physiological solution (12, 129). These staining procedures also lack sensitivity. Observation of yeast cells through direct examination, however, is not conclusive for sporotrichosis diagnosis. The characteristic “cigar-shaped” buds (2 by 3 to 3 by 10 μm) are not always witnessed. Moreover, yeast cells of *H. capsulatum* and *Candida glabrata* may be misidentified as *S. schenckii* (130).

Direct examination of pus obtained from lesions of patients with sporotrichosis, without potassium hydroxide, also permits the detection of asteroid bodies. These structures were confirmed in 43.75% of patients, and the sensitivity of the examination can be enhanced (up to 93.75%) if the initial pus is discarded and new samples are collected more deeply. This can help to initiate specific treatment before the results of the culture examinations are available (78).

### Histopathological Examination

Although *S. schenckii* may be seen in tissue with the routinely used hematoxylin and eosin (H&E) stain, other special stains such as Gomori methenamine silver (GMS) or periodic acid-Schiff (PAS) stain can be employed to enhance fungal detection (130, 170). Fontana-Masson staining is negative (54). Atypical *S. schenckii* cells can appear spherical and surrounded by a PAS-positive capsule, resembling *Cryptococcus* cells (126). Once again, parasitic cells of *S. schenckii* are difficult to visualize due to the paucity of yeasts in lesions from humans (170) or other animals such as dogs (57).

Tissue reaction must be also evaluated in histopathological examinations from patients with sporotrichosis. *S. schenckii* usually causes a mixed supplicative and granulomatous inflammatory reaction in the dermis and subcutaneous tissue, frequently accompanied by microabscess and fibrosis. Cutaneous infections may also exhibit hyperkeratosis, parakeratosis, and pseudoepitheliomatous hyperplasia (130). Foreign bodies of vegetal origin related to the traumatic inoculation of the agent may also be encountered (182).

Besides intact polymorphonuclear cells, granulomas in sporotrichosis usually contain cellular debris, caseous material, giant and epithelioid cell lymphocytes, plasmocytes, and fibroblasts as well as *S. schenckii* yeast cells within phagocytic cells or in the extracellular medium (129). Miranda and collaborators (167) reported that in dogs with sporotrichosis, lesions present well-formed granuloma, with marked neutrophil infiltration. The peripheral infiltrate often is devoid of lymphocytes and macrophages. Taken together, this information enables the differentiation of sporotrichosis and leishmaniasis in these animals.

Some histopathological alterations, such as presence or predominance of epithelioid granulomas, presence of foreign body granulomas, predominance of lymphocytes, presence or predominance of caseous necrosis, and predominance of fibrinoid necrosis and fibrosis, are related to the lack of observation of the fungus in tissue sections from human patients. When the fungus is not in evidence, suppurative granulomas, neutrophils, and liquefaction necrosis are uncommon (187).

Splendore in 1908 described a radiate eosinophilic substance in human tissues from patients with sporotrichosis, and Hoepli in 1932 reported an eosinophilic material around schistosome larvae (126). The Splendore-Hoepli reaction is indicative of a localized immunological host response to antigens of diverse infectious organisms, including fungi, bacteria, and other parasites. It appears as radiating homogenous, refractile, eosinophilic clublike material surrounding a central eosinophilic focus (130). There are several reports concerning asteroid bodies, the Splendore-Hoepli reaction in sporotrichosis, in histopathological tissue sections from sporotrichosis patients, ranging in positivity from 20 to 66% (78). Other authors, however, report an absence of this structure in analyzed samples (187). Yeast cells remain viable inside the asteroid bodies, which present IgG and IgM from the host on the spikes of the radiated crowns, suggesting that asteroid bodies are resistance structures which use immune molecules of the host to advantage the yeasts (203).

### Culture

Definitive sporotrichosis diagnosis is based on the isolation and identification of the etiological agent in culture (126). Isolation of *S. schenckii* is easily obtained after spreading of the clinical specimens on Sabouraud agar with chloramphenicol and on media with cycloheximide, such as mycobiotic agar. After 5 to 7 days of incubation at 25°C, filamentous hyaline colonies start to grow, and after some time, they may develop a dark color, usually in the centers of the colonies (170). To identify an isolate as *S. schenckii*, one must demonstrate that it undergoes dimorphism by subculturing the fungus on enriched media such as brain heart infusion agar, chocolate agar, and blood agar at 35 to 37°C for 5 to 7 days. Occasional isolates can be difficult to convert and may require multiple subcultures and extended incubation (216). After *S. schenckii* conversion to the yeast phase, colonies acquire a creamy aspect and a yellow to tan color (170). Environmental *Sporothrix* strains may also form the yeast phase when grown on appropriate media at 37°C. For this reason, observation of dematiaceous conidia in colonies maintained at 25°C is mandatory (54, 60, 216). For this purpose, slide culture preparations with potato dextrose agar or cornmeal agar are ideal to study *S. schenckii* conidogenesis (54).

Positive cultures provide the strongest evidence for sporotrichosis, allowing diagnosis of almost all cases of cutaneous disease. Nevertheless, culture diagnosis has significant limitations, mainly in some manifestations of the disease such as *S. schenckii* induced arthritis, where the collection of material for culture is difficult.

### Molecular Detection

Nonculture methods have been developed to improve the rate and speed of mycological diagnosis (194, 241). Molecular detection of *S. schenckii* is useful for a rapid diagnosis of sporotrichosis and also valuable in cases of negative cultures due to low fungal burden or secondary infections.

Up to now, there has been a scarcity of molecular methods for the detection of *S. schenckii* DNA from clinical specimens. Sandhu and collaborators (211) reported the development of 21 specific nucleotide probes targeting the large-subunit rRNA genes from several fungi, including *S. schenckii*. The authors adopted a protocol for DNA extraction from clinical specimens that consists of boiling the specimens in an alkaline...
guanidine-phenol-Tris reagent, followed by amplification of a variable region of the 28S rRNA gene with universal primers and amplicon identification using the specific probes. The results displayed a high level of specificity for this test.

Some methodologies to identify *S. schenckii* colonies from pure cultures have been described. Specific probes for fungi with yeast-like morphology in vivo, including all dimorphic fungal pathogens, were developed for the detection of PCR amplicons in an enzyme immunoassay format. *S. schenckii* DNA was able to hybridize to the probe to detect all dimorphic fungi as well as to its specific probe (137). Specific oligonucleotide primers based on the chitin synthase gene were also developed. This primer was able to detect 10 pg of genomic *S. schenckii* DNA (110). Primers to distinguish *S. schenckii* from related species such as *Ceratocystis stenoceras*, based on the DNA topoisomerase II genes, permitted the amplification of fragments of 663 to 817 bp from *S. schenckii* and a 660-bp fragment from *S. schenckii var. laurei*. Another set of primers allowed the amplification of a specific 305-bp fragment from *S. schenckii var. laurei* (109). These detection systems may be useful as diagnostic tools for the detection of human and animal sporotrichosis. In fact, a PCR assay based on the internal transcriber space in the rRNA gene has been used for the identification of an *S. schenckii* strain from an atypical case of sporotrichosis (75).

**Sporotrichin Skin Test**

The cutaneous sporotrichin skin test detects delayed hypersensitivity, i.e., the cellular immune response, and can be a useful diagnostic tool, but its major usefulness is in epidemiological investigations. This reaction is usually positive in about 90% of confirmed sporotrichosis cases but can also indicate previous infection with the fungus (105). The sporotrichin skin test has been successfully applied to confirm the diagnosis of bulbar conjunctival sporotrichosis after the pathological examination revealed yeast-like cells (113).

Epidemiological studies usually involve the sporotrichin skin testing of individuals living or working in a determinate area together with attempts to isolate the fungus from the soil in that area. For instance, this test gave 6.25% positivity in a Mexican state where virulent strains of *S. schenckii* were isolated from soil (210). On the other hand, 13.67% positivity was found among healthy mine workers from Brazil, although the fungus was not isolated from soil samples from the mines investigated (198).

Despite the current use of the sporotrichin skin test in several studies throughout the world, the antigen adopted in these tests lacks standardization. Several studies on sporotrichin in Brazil were performed with a 5 McFarland standard suspension of heat-killed yeast cells (129). A retrospective 10-year study in Mexico used extracted mycelial antigens at a 1:2,000 dilution (28), while another Mexican study diluted yeast-phase antigens at 1:4,000 (210). These variations in antigen production may lead to differences in results.

**Antibody Detection**

Several methodologies have been described for the immunological diagnosis of sporotrichosis based on antibody detection in sera from infected patients. Precipitation and agglutination techniques were first adopted. Double immunodiffusion for sporotrichosis does not usually show cross-reactions with sera from patients with chromoblastomycosis or leishmaniasis, infectious diseases with similar clinical manifestations. Immunoelectrophoresis has also been employed, with an anodic arc, called S arc, being observed in all positive cases (2). Tube agglutination and latex agglutination have been utilized for sporotrichosis serodiagnosis since the 1970s, and very good sensitivity (96% and 94%, respectively) and specificity (98 and 100%, respectively) have been observed (26, 41, 112). These tests, however, lack sensitivity in cases of cutaneous sporotrichosis (2, 196) and do not permit the determination of the immunoglobulin isotype involved in the response.

Immunoenzymatic assays are currently being used more frequently for serodiagnosis purposes. The publication of an immunoblot assay for serodiagnosis of sporotrichosis dates back to 1989, when molecules of 40 and 70 kDa from exoantigen preparations from the *S. schenckii* yeast form showed 100% sensitivity and 95% specificity (229). Our group, however, in an attempt to reproduce these data, found high cross-reactivity of this antigenic preparation with sera from patients with paracoccidioidomycosis (unpublished results), which is not an endemic disease in the United States, where the first study was conducted.

Antibodies against a concanavalin A binding peptide-rhamnomanan from the *S. schenckii* yeast cell wall could be detected in an enzyme-linked immunosorbent assay (ELISA), showing 100% sensitivity when 35 serum samples from patients with culture-proven sporotrichosis were tested. However, sera from patients with cutaneous leishmaniasis showed cross-reactions in this assay format (140). This antigenic preparation was further evaluated with sera from 92 patients with sporotrichosis in Rio de Janeiro and 77 heterologous sera, with 90% sensitivity and 80% specificity (23). Other studies showed that the use of different strains in the preparation of the antigen may lead to different sensitivity and specificity results, despite the process of purification of the antigen involved in this methodology. This difference is due to O-glycan residues linked to the molecules. The strain that had better results was the 1099-18 strain obtained from the Mycology Section, Department of Dermatology, Columbia University, New York, NY (24).

Efforts to contribute to this field culminated in the development of an enzyme immunoassay with exoantigens produced by a mycelial-phase *S. schenckii* strain isolated during the Rio de Janeiro epidemic of sporotrichosis (7). This antigen was described by Mendoza and collaborators (161) and had no cross-reaction with antigens and serum samples from patients with coccidioidomycosis, histoplasmosis, or paracoccidioidomycosis. The same antigen was previously used in immunodiffusion and immunoelectrophoresis techniques, without cross-reactions with sera from patients with leishmaniasis or chromoblastomycosis (2). The methodology for production of this antigen is simple and does not require chromatographic steps, making it easy for laboratories with limited resources (7), although more variations can occur with this kind of preparation than with those involving purification procedures.

Detection of IgG antibodies against these exoantigens distinguished 90 sera from patients with different clinical forms of...
sporotrichosis, 72 sera from patients with other infectious diseases, and 76 sera from healthy controls, yielding 97% sensitivity and 89% specificity (7). These values are slightly higher than those for the concanavalin A binding fraction of the \textit{S. schenckii} yeast cell wall (23), and similar observations were made with this purified antigen and crude exoantigens in the serodiagnosis of feline sporotrichosis. Purified antigens exhibited 90% sensitivity and 96% specificity, whereas crude exoantigens showed 96% sensitivity and 98% specificity (65). It has also been demonstrated that in order to improve the overall efficiency of antibody detection for diagnosis and follow-up of human sporotrichosis with the mycelial exoantigen preparation, a search for IgG and IgA antibodies for diagnosis and a search for IgG and IgM antibodies for follow-up purposes must be undertaken (6).

Importantly, the results from all antibody detection tests provide a presumptive diagnosis of sporotrichosis and require clinical and epidemiological correlation for an accurate evaluation and determination of the final diagnosis.

**EPIDEMIOLOGY**

The natural history of sporotrichosis has been changing gradually in frequency, mode of transmission, and demographic and geographic distributions. It is possible that environmental factors, increased urbanization, and improved diagnostics partly explain the alterations in the profile of the disease. Furthermore, since sporotrichosis is not a reportable disease in most countries, there is little information on the incidence, and the known data are those generated by case publications.

**Geographic Distribution**

At the beginning of the last century, sporotrichosis was a common disease in France; it declined after 2 decades and today sporadically appears in Europe. In 2009, an autochthonous case was reported in France (146), and in 2008, another one was reported in the southern region of Italy (49), but these reports are rare and isolated. Despite having been described on five continents, sporotrichosis has a higher prevalence in tropical and temperate zones. The main areas of endemicity are located in Japan (248), India (156), Mexico (144), Brazil (17, 218, 222), Uruguay (45, 47), and Peru (124). In the United States, especially in the Mississippi Valley, outbreaks related to pine seedlings and manipulation of moss have been cited (185).

A bibliography search performed in PubMed with the term “\textit{Sporothrix schenckii}” or “sporotrichosis” for the last 10 years (from January 2001 to November 2010) yielded 407 results. Of these, 83 were excluded (because they were book chapters, reports of other diseases, etc.). Of the remaining 324 references retrieved, 142 were case reports and case series for humans, 22 were case reports and case series for animals, 119 were laboratory studies (molecular studies, antifungal susceptibility tests, environmental studies, etc.), and 41 were various (reviews, letters, comments, or guidelines). These 324 publications were produced by authors from 27 countries. Obviously, these data reflect solely the scientific papers published by workers in these countries, and it is not possible to correlate with disease prevalence (Fig. 6). In the United States, where the incidence of cases is low and usually related to handling sphagnum moss (92), the large number of publications reflects the development of research in the country. The lack of infrastructure for laboratory diagnosis and the lack of research in many countries do not allow for accurate knowledge of disease distribution and environmental sources of the fungus. Newton et al. (175), reporting a case of cutaneous-lymphatic sporotrichosis in a patient from Laos, highlighted the difficulties in laboratory diagnosis of fungal infections in Southeast Asian countries, resulting in a shortage of reports. These authors point out that in regions such as the highlands of China, Laos, Vietnam, and Burma, which have favorable conditions for \textit{Sporothrix} growth, the prevalence of cases must be much higher than is estimated according to the literature.

**Distribution by Age and Gender**

Sporotrichosis affects both genders and all ages. In most regions, the difference in case distribution by age and sex is related to occupation and exposure to the fungus. Among the cases studied by Takenaka et al. (248), 70% were older than 50 years, with an equal division between sexes. In Japan, where that study was conducted, working in agricultural activities has been associated with a higher risk for acquiring sporotrichosis. In Colombia (205) and the southern region of Brazil (10), there was a higher prevalence in men over 40 who were involved in agricultural activities as well as other high-risk activities. Also in Brazil, in the state of Rio de Janeiro, there was a predominance in women over 40 who were involved in housework and the care of cats with sporotrichosis, the highest risk group for acquiring the disease (18, 218). In Abancay, a rural area of Peru, of the 238 cases studied from 1995 to 1997, 60% occurred in children younger than 15 years old. In that study, no association between age, sex, and exposure to the fungus could be found (184).

**Transmission and Sources of Infection**

Sporotrichosis has been traditionally known as “gardeners’ disease,” especially affecting those involved in the cultivation of roses (62). Although in most cases the infection results from inoculation of the fungus by thorn or other pricks, scratches, and other small injuries, a history of trauma can be absent (17, 184, 191). Certain occupational and leisure activities, such as floriculture, horticulture, gardening, fishing, hunting, farming, mining, and others that facilitate exposure to the fungus, have over the years been associated with the transmission of the disease (196). In Uruguay, and more recently in southern Brazil, the hunting of armadillos has been related to cases of sporotrichosis (10, 47). There have been reports of the mycosis following bites or scratches by animals such as cats and squirrels, insect bites, and other injuries. These conditions may either result in direct inoculation or facilitate the entry of the fungus (15, 166). In some situations, such as in an area of endemicity in Peru, the mode of transmission had not been made clear (115, 184) until another study in the same region identified the ownership of cats, outdoor activities, and low socioeconomic status as risk factors for acquiring sporotrichosis (142). Some cases have been reported in laboratory professionals who were infected by manipulating cultures of \textit{S. schenckii} (48). Interhuman transmission is rare (215). Sporo-
trichosis usually occurs in isolated cases or small outbreaks in families and professionals engaged in high-risk activities. Epidemics are rare and, when they occur, are commonly related to a single source of infection (30). The largest outbreak occurred in Witwatersrand, South Africa, and its description contributed significantly to the current knowledge of sporotrichosis, representing so far the most complete epidemiological investigation of the disease. Between 1941 and 1944, more than 3,000 gold miners were infected by the fungus, which was present in the timber of these mines (96). In the United States, the largest epidemic took place in 1988 and involved a total of 84 cases in 15 states, affecting workers who participated in reforestation programs. The cases were associated with exposure to sphagnum moss used for the packing of seedlings from a nursery in Pennsylvania (42).

**Zoonotic Transmission**

Sporotrichosis has been sporadically associated with scratches or bites from animals such as mice, armadillos, squirrels, dogs, and cats (114). The role of felines in the transmission of the mycosis has gained attention since the 1980s, when Read and Sperling (191) reported an outbreak involving five people exposed to a cat with sporotrichosis. Since then, successive reports from different geographical regions have characterized a new risk group for acquisition of sporotrichosis, composed of
cat owners and veterinarians (98, 269). The first epidemic of zoonotic sporotrichosis was detected in Rio de Janeiro (17, 222). From 1998 to December 2009, more than 2,000 cases in humans and over 3,000 cases in cats were diagnosed at Instituto de Pesquisa Clínica Evandro Chagas (IPEC)/Fiocruz, representing the largest epidemic of zoonotic transmission of this mycosis ever recorded (19). A study of 178 human cases assessed from 1998 to 2001 showed that of 156 patients who reported professional or household contact with cats with sporotrichosis, 97 had been scratched or bitten by these animals (17). Some authors believe that cats are the only animals with zoonotic transmission potential because of the large amount of yeast cells in the lesions (225, 245). Although dogs have also been affected, they do not seem to have significant zoonotic transmission potential because of the large amount of cat-transmitted sporotrichosis, infection by the yeast form can also occur. This hypothesis is based on the large amount of this form in the lesions from cats associated with transmission without a history of scratches or bites (18). Moreover, the isolation of yeast forms in cats’ claws also favors this idea (226). A molecular study revealed that DNA fingerprints of S. schenckii isolated from the nails and the oral cavities of cats were identical to those of related human samples, suggesting that there is a common infection source for animals and humans in the current epidemic in Rio de Janeiro (192). It is clear that cats act as a vehicle for S. schenckii dissemination. However, the lack of environmental studies on this epidemic and the deficit of information on natural sources that can serve as a reservoir of the fungus do not allow a conclusion to be drawn. The fixed form is represented by a single lesion or a few lesions at the inoculation site, which is often ulcerated with erythematous edges. The morphology can also be vegetative, verrucous, plaque infiltrated, or tuberous, without lymphatic involvement. Some cases may spontaneously regress (4). Most authors report the fixed cutaneous form as the main clinical presentation in children (252). However, the lymphocutaneous form is the most frequent overall, being present in more than 75% of cases (28, 190). The primary lesion is usually located on the extremities, especially hands and forearms, corresponding to the sites most exposed to trauma. Initially, a papule or pustule is followed by formation of a subcutaneous nodule. This lesion, exerting pressure beneath the skin, causes ischemia under the epidermis, evolves into gum, ulcerates, and oozes a purulent secretion. With the progression, secondary lesions arise along the path of regional lymphatics, featuring “sporotrichoid aspect” of the infection. Lymph node involvement or the presence of systemic symptoms is unusual.

A disseminated cutaneous form is characterized by multiple skin lesions at noncontiguous sites without extracutaneous involvement. Lesions of the fixed and lymphocutaneous forms may coexist in the same patient. Until the emergence of zoonotic transmission, this form was rare and was caused by hematogenous spread of the fungus, usually associated with immunosuppression (39, 239). In transmission by cats, several inoculations in different locations may occur, during either treatment or play with animals (20). Although there is a dis-
tinct pathogenesis for each situation, it is difficult to identify whether the clinical presentation is due to dissemination from a single lesion or to multiple inoculations.

**Mucosal form.** Some authors consider the mucosal form to be a variant of the cutaneous form. In the nasal mucosa, the lesions often involve the septum, with drainage of bloody secretions and detachment of crusts. In the conjunctiva, the granulomatous lesion is accompanied by a serous-purulent discharge, redness, and presence or not of lid edema (219). Mucosal forms are frequently accompanied by preauricular and submandibular lymph node enlargement (93, 219). These signs can be a consequence of self-inoculation through hands contaminated with the fungus, hematogenous dissemination, and inhalation of conidia (18, 20, 93). Although rare, conjunctival and nasal mucosal involvement has been diagnosed even in pediatric patients (16, 218). In cats with sporotrichosis, the nose is the most affected region and respiratory signs are common (83, 222). As the owners play with their animals in close contact, transmission is made easier.

**Extracutaneous form.** The extracutaneous forms are rare and difficult to diagnose, although they are more frequent after the onset of AIDS (31, 94, 234, 263). After the skin, bone tissue is the most affected. The osteoarticular form may occur by contiguity or hematogenous spread (120, 170). The lesions may vary from small granulomas to large lytic lesions identical to osteomyelitis (125). One or several joints and bones can be involved, as well as tenosynovitis or bursitis (115, 227). In immunocompetent patients, monoarthritis is more frequent than multiple articular involvement. The rarity of musculoskeletal disease in addition to the scarcity of fungal elements in synovial fluid culture and synovial histopathology often delays the diagnosis (11). According to Howell and Toohey, there were only 51 cases of sporotrichal arthritis reported in the English literature up to 1998 (102). Primary pulmonary sporotrichosis, resulting from inhalation of the fungus, is usually associated with chronic obstructive pulmonary disease, alcoholism, chronic use of corticosteroids and, immunosuppressive diseases (189). The clinical presentation is similar to that of tuberculosis, and the diagnosis is often delayed due to the rarity of pulmonary involvement. Radiological patterns include cavitary disease, tracheobronchial lymph nodes enlargement, and nodular lesions (183). Systemic sporotrichosis is extremely rare and always associated with immune system deficiency. De Beurmann and Gougerot (51) had suggested that sporotrichosis could be considered an opportunistic disease. Most of their patients had some comorbidity, and all cases with the extracutaneous form presented impaired health or malnutrition. Reports on meningitis associated with *Sporothrix* infection are not frequent, and these cases are often associated with immunological impairment, mainly after onset of HIV infection. Diagnosis of this form of chronic meningitis is challenging because of the rarity of demonstration of *Sporothrix schenckii* in smears of cerebrospinal fluid and the difficulty in isolating the yeast on culture. Thus, any other method that provides early and specific diagnosis, such as antibody detection in cerebrospinal fluid, may be helpful in the diagnosis (23, 228). According to Salaki et al. (209), there has been a marked increase in the number of reported cases of meningitis and brain abscess due to fungi and yeasts. This increase is due in part to better diagnostic techniques and greater awareness of the possibility of fungal invasion of the nervous system, but the increase can also be attributed to a growing pool of severely compromised hosts. Besides AIDS, other conditions such as diabetes, alcoholism, granulomatous diseases, cirrhosis, renal transplantation, malignancies, corticosteroids, and use of immunosuppressive agents are commonly reported in patients with extracutaneous sporotrichosis (72, 82, 85). HIV-infected patients with preserved immunity seem to respond to infection by *Sporothrix schenckii* in the same way as individuals without coinfection (220). In patients with AIDS, sporotrichosis assumes the role of an opportunistic disease, with severe cases, systemic involvement, and often spread to the meninges (263). Skin lesions may be atypical, with a minimal inflammatory response (114). There are cases of disseminated sporotrichosis described in the literature as the first manifestation of AIDS (8) and associated with immune reconstitution inflammatory syndrome (76, 87).

**Associated signs and symptoms.** Erythema nodosum and erythema multiforme have been reported in cases of sporotrichosis by zoonotic transmission. These conditions appear to be associated with a hypersensitivity reaction, resulting from continuous exposure to large amounts of fungus and subclinical reinfections (86, 89).

**Differential diagnosis.** The differential diagnoses should be considered in accordance with the diversity of clinical forms and the morphology of the lesions. In the fixed form, the main differential diagnosis is cutaneous leishmaniasis. A study with application of the Montenegro skin test in 107 cases of sporotrichosis in Rio de Janeiro from 1998 to 2001 produced 48.6% positivity (21). In such cases, only mycological and parasitological examinations can establish a definitive diagnosis. Apart from cutaneous leishmaniasis, other causes, including noninfectious skin ulcers, should be considered. In the lymphocutaneous form, other disorders that present nodular lymphangitis should be investigated (58, 253), particularly mycobacteriosis. Among the mycobacteria, *Mycobacterium marinum* infection often accompanies lymphocutaneous lesions. There has been a report of sporotrichoid infection caused by *Mycobacterium fortuitum* in a pregnant woman (208). Nocardiosis (caused mainly by *Nocardia brasiliensis*), chromoblastomycosis, cryptococcosis, Blastomycosis, and cat scratch disease also can be differential diagnoses. Sporotrichosis can also mimic cutaneous bacterial infections, sarcoidosis, lupus vulgaris, tuberculosis, and scrofuloderma, among others (11, 188, 268). These conditions should be differentiated by history, areas of endemicity, and lab tests.

**Feline Disease**

De Beurmann et al. (52) experimentally demonstrated the susceptibility of cats to *S. schenckii* in 1909. However, naturally acquired feline sporotrichosis was reported only in 1952 by Singer and Muncie (236). Sporotrichosis in cats has been considered to be sporadic and transmission to humans to be accidental (61). In 1998 the first epizootic of cat sporotrichosis was detected. By December 2010, over 3,000 cases in cats were diagnosed at Fiocruz/Rio de Janeiro (19). A study by Schubach et al. evaluated 337 cats with sporotrichosis diagnosed by isolation of *S. schenckii* in culture, 10 asymptomatic cat carriers, and 91 asymptomatic apparently healthy cats in the period...
from 1998 to 2001 (221, 222). In those 4 years of monitoring the epidemic, there was a broad spectrum in clinical presentation, ranging from subclinical infection to single lesions with spontaneous regression to fatal systemic forms. The lymphocutaneous form was determined in only 19.3% of the cases, the involvement of the mucous membranes of the respiratory tract and upper digestive tract in 34.9%, and multiple cutaneous lesions in 39.5% (222). Systemic disease was demonstrated by in vivo detection of \textit{S. schenckii} in the skin and various internal organs in 10 cats necropsied (225). In cats, unlike in humans, the low frequency of granuloma (12%) and the richness of fungal elements found in the histopathology of the skin demonstrate the increased susceptibility of animals to \textit{S. schenckii} (222). An evaluation of 142 cats with sporotrichosis regarding feline immunodeficiency virus (FIV) and/or feline leukemia virus (FeLV) infection revealed 21.8% positivity (222). There were no significant differences in clinical and laboratory profiles between animals coinfected and not coinfected with FIV and/or FeLV. Unlike in humans, in whom disseminated sporotrichosis typically affects immunocompromised individuals, systemic disease in cats was frequent and was not associated with immunodeficiency caused by FIV and/or FeLV.

**TREATMENT**

Potassium iodide has been traditionally used in the treatment of sporotrichosis since the early 20th century, with satisfactory results (51). Some suggest that this salt acts on the resolution of granulomas through increased proteolysis (196), while others claim that it promotes an increase of phagocytosis. However, the exact mechanism of action remains unknown. Due to adverse effects related to this medication, in the 1990s theazole compounds were introduced, and itraconazole is currently the first-choice treatment (115). Itraconazole has been used effectively and safely in most cases of sporotrichosis, with low toxicity and good tolerance, even in long-term treatments. The dose varies from 100 to 200 mg/day orally for cutaneous and lymphocutaneous forms. A dose of 400 mg/day orally should be administered for cutaneous forms with a poor initial response to a lower dosage, for osteoarticular forms, for pulmonary forms, and as suppressive therapy in immunocompromised patients after induction with amphotericin B. For children weighing up to 20 kg, 5 to 10 mg/kg/day is recommended. Itraconazole is metabolized by the cytochrome P450 3A4 and has numerous drug interactions associated with the inhibition or induction of this system. The drug is contraindicated in pregnancy, and women of childbearing age should be counseled in favor of effective contraceptive methods. The safety and efficacy of itraconazole were evaluated in 645 patients with culture-proven sporotrichosis from Rio de Janeiro, Brazil. Six hundred ten (99.6%) of the patients were cured with itraconazole (50 to 400 mg/day), 547 with 100 mg/day, 59 with 200 to 400 mg/day, and 4 children with 50 mg/day. Four hundred sixty-two (71.6%) completed clinical follow-up for 3 to 6 months, and all remained cured. This study highlighted the good response to a minimal dose of itraconazole (55). Several reports have demonstrated the excellent efficacy and tolerability of the drug, even for the disseminated cutaneous and extracutaneous forms (119, 149, 165, 239, 268). The intermittent administration of itraconazole in pulses of 400 mg/day orally for 1 week has also been studied (27). A randomized controlled study comparing the safety and efficacy of an itraconazole pulse regimen to a continuous regimen for cutaneous sporotrichosis found similar results for both groups (238). Potassium iodide and itraconazole are contraindicated in pregnant women. These patients can use thermotherapy with daily application of local heat (42 to 43°C) through a hot water bag, a source of infrared, or a similar method until healing of the lesions (115). The mechanism of action of local heat has been demonstrated in the laboratory. When cells of \textit{S. schenckii} in serum are incubated with neutrophils at 40°C and 37°C, there is no difference related to phagocytosis in the two groups. However, once the cells are phagocytosed, the death rate of the fungus is higher at 40°C than at 37°C (99). Amphotericin B has been given for initial treatment of disseminated forms, particularly in immunocompromised subjects (115). Patients coinfected with HIV should subsequently receive suppressive therapy with itraconazole until immune system restoration. In pregnant women, amphotericin B may be used after 12 weeks of pregnancy, but this medication is to be reserved for pulmonary and disseminated forms for which treatment cannot be delayed. Fluconazole is less effective than itraconazole and is given to patients who do not tolerate or have drug interactions with itraconazole. Ketoconazole, in addition to having greater toxicity, has not demonstrated a good response (115).

Susceptibility studies concerning good in vitro activity of terbinafine and posaconazole against \textit{Sporothrix schenckii} have been encouraging (157, 235). The three studies using terbinafine in human patients demonstrated a good efficacy for doses ranging from 250 to 1,000 mg/day (43, 73, 74). A study comparing 250 mg/day of terbinafine to 100 mg/day of itraconazole resulted in healing in 92.7% and 92% of patients, respectively, indicating terbinafine to be an effective and well-tolerated option for the treatment of cutaneous sporotrichosis (73). However, the cost, which is even higher than that of itraconazole, is a barrier for developing countries. Posaconazole is a broad-spectrum triazole, but its use in clinical sporotrichosis is yet to be evaluated (214, 235). Susceptibility testing with voriconazole, ravuconazole, micafungin, and other new antifungal agents is still incipient, and so far there is no indication for use of these drugs for the treatment of sporotrichosis (9, 169, 178, 233). There are studies showing different results for the same antifungal agent according to geographic area, the species of \textit{Sporothrix}, and the method used (9, 88, 169).

**Antifungal Susceptibility Tests**

Nowadays, there is an ever-increasing interest in testing the susceptibilities of filamentous and yeast fungal pathogens to the available antifungal drugs (80). Of the available methods, two are standardized for \textit{S. schenckii} testing. The Clinical and Laboratory Standards Institute (CLSI) proposes a microdilution test with a test inoculum of $0.4 \times 10^3$ to $5 \times 10^3$ CFU/ml, rendered from a 7-day-old \textit{S. schenckii} filamentous colony, used to inoculate RPMI 1640 medium, where antifungal drugs are serially diluted and, after 46 to 50 h of incubation at 35°C without agitation, MICs determined (46). Another protocol for \textit{S. schenckii} antifungal susceptibility testing was elaborated by the European Committee for Antimicrobial Susceptibility

---

[51x89]reports have demonstrated the excellent efficacy and tolerability of the drug, even for the disseminated cutaneous and extracutaneous forms (119, 149, 165, 239, 268). The intermittent administration of itraconazole in pulses of 400 mg/day orally for 1 week has also been studied (27). A randomized controlled study comparing the safety and efficacy of an itraconazole pulse regimen to a continuous regimen for cutaneous sporotrichosis found similar results for both groups (238). Potassium iodide and itraconazole are contraindicated in pregnant women. These patients can use thermotherapy with daily application of local heat (42 to 43°C) through a hot water bag, a source of infrared, or a similar method until healing of the lesions (115). The mechanism of action of local heat has been demonstrated in the laboratory. When cells of \textit{S. schenckii} in serum are incubated with neutrophils at 40°C and 37°C, there is no difference related to phagocytosis in the two groups. However, once the cells are phagocytosed, the death rate of the fungus is higher at 40°C than at 37°C (99). Amphotericin B has been given for initial treatment of disseminated forms, particularly in immunocompromised subjects (115). Patients coinfected with HIV should subsequently receive suppressive therapy with itraconazole until immune system restoration. In pregnant women, amphotericin B may be used after 12 weeks of pregnancy, but this medication is to be reserved for pulmonary and disseminated forms for which treatment cannot be delayed. Fluconazole is less effective than itraconazole and is given to patients who do not tolerate or have drug interactions with itraconazole. Ketoconazole, in addition to having greater toxicity, has not demonstrated a good response (115).

Susceptibility studies concerning good in vitro activity of terbinafine and posaconazole against \textit{Sporothrix schenckii} have been encouraging (157, 235). The three studies using terbinafine in human patients demonstrated a good efficacy for doses ranging from 250 to 1,000 mg/day (43, 73, 74). A study comparing 250 mg/day of terbinafine to 100 mg/day of itraconazole resulted in healing in 92.7% and 92% of patients, respectively, indicating terbinafine to be an effective and well-tolerated option for the treatment of cutaneous sporotrichosis (73). However, the cost, which is even higher than that of itraconazole, is a barrier for developing countries. Posaconazole is a broad-spectrum triazole, but its use in clinical sporotrichosis is yet to be evaluated (214, 235). Susceptibility testing with voriconazole, ravuconazole, micafungin, and other new antifungal agents is still incipient, and so far there is no indication for use of these drugs for the treatment of sporotrichosis (9, 169, 178, 233). There are studies showing different results for the same antifungal agent according to geographic area, the species of \textit{Sporothrix}, and the method used (9, 88, 169).

**Antifungal Susceptibility Tests**

Nowadays, there is an ever-increasing interest in testing the susceptibilities of filamentous and yeast fungal pathogens to the available antifungal drugs (80). Of the available methods, two are standardized for \textit{S. schenckii} testing. The Clinical and Laboratory Standards Institute (CLSI) proposes a microdilution test with a test inoculum of $0.4 \times 10^3$ to $5 \times 10^3$ CFU/ml, rendered from a 7-day-old \textit{S. schenckii} filamentous colony, used to inoculate RPMI 1640 medium, where antifungal drugs are serially diluted and, after 46 to 50 h of incubation at 35°C without agitation, MICs determined (46). Another protocol for \textit{S. schenckii} antifungal susceptibility testing was elaborated by the European Committee for Antimicrobial Susceptibility
TABLE 1. MIC ranges for 13 antifungal drugs against S. schenckii described in various publications

| Reference | Location       | No. of strains analyzed | MIC (µg/ml)  
|-----------|----------------|-------------------------|--------------
| 64        | USA            | 5                       | AMB 0.5–16   |
|           |                |                         | FLC 64       |
|           |                |                         | ITR 0.03–16  |
|           |                |                         | KET 0.25–4   |
|           |                |                         | VOR 0.12–>16 |
| 106       | UK             | 10                      | AMB 0.5–4    |
|           |                |                         | FLC NT       |
|           |                |                         | ITR 0.06–>16 |
|           |                |                         | KET NT       |
| 155       | Not reported   | 100                     | AMB 0.25–2   |
|           |                |                         | FLC NT       |
|           |                |                         | ITR NT       |
| 172       | Japan          | 7                       | AMB 1–2      |
|           |                |                         | FLC >64      |
|           |                |                         | ITR 0.5–1    |
| 121       | Brazil         | 30                      | AMB NT       |
|           |                |                         | FLC NT       |
|           |                |                         | ITR 0.06–4   |
| 179       | USA            | 3                       | AMB 1–4      |
|           |                |                         | FLC NT       |
|           |                |                         | ITR NT       |
| 169       | Peru           | 22                      | AMB NT       |
|           |                |                         | FLC NT       |
|           |                |                         | ITR 0.06–1   |
| 81        | Mexico         | 15                      | AMB NT       |
|           |                |                         | FLC NT       |
|           |                |                         | ITR NT       |
| 258       | Brazil         | 34                      | AMB 1–4      |
|           |                |                         | FLC >64      |
|           |                |                         | ITR 0.25–>16 |
| 122       | Brazil         | 43                      | AMB 0.5–8    |
|           |                |                         | FLC NT       |
|           |                |                         | ITR 0.25–4   |
| 10        | Peru           | 19                      | AMB 0.06–>16 |
|           |                |                         | FLC >64      |
|           |                |                         | ITR 0.25–1   |
|           |                |                         | KET 0.06–0.5 |
| 157       | Brazil         | 12                      | AMB NT       |
|           |                |                         | FLC NT       |
|           |                |                         | ITR 0.2–1.75 |
| 91        | Brazil/Spain   | 88                      | AMB 0.12–4   |
|           |                |                         | FLC 64       |
|           |                |                         | ITR 0.12–>8  |
| 152       | Several        | 92                      | AMB 0.5–32   |
|           |                |                         | FLC 128      |
|           |                |                         | ITR 0.5–32   |
|           |                |                         | KET 0.06–8   |
| 208       | Not reported   | 10                      | AMB NT       |
|           |                |                         | FLC NT       |
|           |                |                         | ITR 0.5–2    |
| 235       | Several        | 62                      | AMB 0.03–16  |
|           |                |                         | FLC NT       |
|           |                |                         | ITR NT       |

a Results were obtained by microdilution reference methods unless otherwise specified.

AMB, amphotericin B; FLC, fluconazole; ITR, itraconazole; KET, ketoconazole; VOR, voriconazole; MFG, micafungin; ADF, anidulafungin; TRB, terbinafine; SFC, 5-fluorocytosine; RVC, ravuconazole; POS, posaconazole; ABC, albiconazole; EBC, eberconazole; NT, not tested.

b MIC was determined by the Etest method.

c The MIC was determined by the Etest method.

Testing (EUCAST), which uses final test inoculums of 1 × 10⁵ to 2.5 × 10⁶ CFU/ml obtained from 2- to 5-day-old cultures to inoculate microplates with RPMI 1640 supplemented with 2% glucose. The endpoint is read visually after a 48 h of incubation at 35 ± 2°C (201).

Commercial methods for S. schenckii susceptibility testing, however, have been adopted by some investigators. The Etest technique shows average agreement rates of 77.5% and 87.8% for amphotericin B and voriconazole, and for itraconazole determined by Etest were significantly lower (56.4% and 54.5%, respectively. MIC values for itraconazole and voriconazole, agreement is lower (9).

Agreements of above 80% were found for amphotericin B and posaconazole, and for itraconazole and voriconazole (87) in a study with Brazilian and Spanish S. schenckii strains. Another study found similar MICs for itraconazole and terbinafine, although the MIC of amphotericin B was slightly higher for mycelia (122). It has been also demonstrated that micafungin is more active against the mycelial than the yeast S. schenckii form (172). Table 1 displays the MIC range for several drugs tested in 16 different studies concerning S. schenckii susceptibility profiles. Since the methodologies used in these studies may have slight differences, comparison of results is difficult. However, some conclusions can be reached. MICs for S. schenckii show high variability (63), as we can see in studies on itraconazole susceptibility. S. schenckii susceptibility to this triazole drug ranges from 0.03 to more than 16 µg/ml. Although some strains can show resistance to this drug, geometric means commonly are low, ranging from 0.4 µg/ml (9) to 4.08 µg/ml (257). In general, despite the use of fluconazole as a therapeutic agent in some human and veterinary sporotrichosis cases (31, 50), this antifungal does not inhibit S. schenckii growth in vitro (9, 63, 90, 152, 172, 257). Some S. schenckii strains are susceptible to voriconazole in vitro, since MIC values of as low as 0.12 µg/ml have been found (107); however, the high geometric mean MIC values, ranging from 6.50 µg/ml (155) to 13.2 µg/ml (152), suggest that most isolates are resistant in vitro to this drug. High micafungin MIC values have been reported by all but one study (152, 172, 207, 257). However, the interaction of micafungin and itraconazole shows a synergy against S. schenckii (207).

The geographic distribution of S. schenckii strains also appears to play an important role in antifungal susceptibility. Strains from the sporotrichosis area of endemicity in Rio de Janeiro are more susceptible to itraconazole and terbinafine than strains from Spain or São Paulo, a neighbor state Rio de Janeiro in Brazil (90). Low terbinafine MIC values were described for strains from Venezuela, and high minimal fungicidal concentration values for posaconazole were found in Peruvian strains (235). This behavior must be related to differences in susceptibility of the newly characterized species.
from the *Sporothrix* complex. In fact, *S. mexicana* shows high MIC values of amphotericin B and several azoles, being susceptible to terbinafine only. *S. brasiliensis* also is more susceptible to azole drugs than the other species (152).

**PREVENTION**

Most cases of sporotrichosis occur when the fungus is introduced through a cut or puncture in the skin while handling vegetation or organic matter containing the fungal spores. Control measures include wearing gloves and long sleeves during high-risk activities such as handling sphagnum moss, wires, rose bushes, hay bales, conifer (pine) seedlings, or other materials that may facilitate the exposure to the fungus. A study by Hajjeh et al. (92) showed that the risk of sporotrichosis increased significantly with the duration of working with sphagnum moss, in particular with filling topiaries, and with having less gardening experience. Wearing gloves was protective. It is also advisable to wear heavy boots to prevent puncture wounds.

Sporotrichosis in cats requires preventive measures to avoid transmission within the species and from animals to humans. Due to the itinerant nature of cats, where males frequently engage in disputes over females, infection is quite common. Cats with sporotrichosis should be correctly treated and kept isolated in a proper place. Any physical contact with the animal should be avoided until complete healing of the lesions. When handling the sick cat, during either injury treatment or medication administration, protocols must be adopted to reduce exposure to the fungus, such as using latex gloves. Another important measure is not to abandon the animal, as this facilitates the dissemination of the disease. In the case of cats with extensive lesions and no possibility of treatment, euthanasia and cremation of the body should be standard procedures in a veterinary health center. Castration encumbers the instinct of hunting, mating, and roaming the neighborhood, therefore reducing the chance of transmission of the mycosis. Some intervention in the environment may be necessary, such as cleaning yards and removing remnants of construction materials and decaying organic matter debris. Only the treatment of sick cats and measures regarding feline sporotrichosis will afford zoonotic transmission control (19).

**ACKNOWLEDGMENTS**

We thank Rosani Santos Reis, who kindly provided Fig. 5. This study was partially supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil, by the programa de Apoio a Pesquisa Estratégica em Saúde (PAPES)—Fundação Oswaldo Cruz (Fiocruz)/CNPq, and by the Fundação de Apoia a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil.

**REFERENCES**


**TABLE 1—Continued**

<table>
<thead>
<tr>
<th>MFG</th>
<th>ADF</th>
<th>TRB</th>
<th>SFC</th>
<th>RVC</th>
<th>POS</th>
<th>ABC</th>
<th>EBC</th>
</tr>
</thead>
<tbody>
<tr>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>0.5–1</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>0.007–0.5</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>2–4</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>&gt;128</td>
<td>NT</td>
<td>0.12–4</td>
<td>16–64</td>
<td>1–16</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>0.015–1</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>0.05–0.875</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>0.02–&gt;16</td>
<td>4–64</td>
<td>0.12–&gt;8</td>
<td>0.06–&gt;8</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>256</td>
<td>NT</td>
<td>0.06–4</td>
<td>1–128</td>
<td>0.06–32</td>
<td>0.25–16</td>
<td>0.25–32</td>
<td>0.06–32</td>
</tr>
<tr>
<td>2–64</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
</tr>
<tr>
<td>NT</td>
<td>0.03–1</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>0.03–2</td>
<td>NT</td>
<td>NT</td>
</tr>
</tbody>
</table>

**TABLE 1**
Sporothrix schenckii and sporotrichosis


139. Reference deleted.


Mônica Bastos de Lima Barros obtained her medical degree from the Federal University of the State of Rio de Janeiro, Brazil, in 1984. She completed her residency in public health at Oswaldo Cruz Foundation and subsequently her M.Sc. and Ph.D. degrees in infectious diseases from the Federal University of Rio de Janeiro. Her thesis was on sporotrichosis and the first description of an epidemic due to zoonotic transmission. During the past 10 years she has gained broad experience in the clinical aspects, epidemiology, treatment, and prevention of sporotrichosis. She works as a researcher and professor at the Oswaldo Cruz Foundation, affiliated with the Ministry of Health, developing studies in infectious diseases.

Rodrigo Almeida Paes obtained his undergraduate degree from the Federal University of the State of Rio de Janeiro, Brazil, in 2004. Since 2002 he has worked at the Oswaldo Cruz Foundation, where he completed his M.Sc. degree in cellular and molecular biology in 2007. He is now a Ph.D. student, working on several aspects of S. schenckii virulence. He is also the supervisor of the Mycological Diagnosis section of the Mycology Laboratory of the Oswaldo Cruz Foundation and teaches medical mycology to technicians and undergraduate students.

Armando de Oliveira Schubach obtained his medical degree from the University of the State of Rio de Janeiro, Brazil, in 1980, a specialization in dermatology from the Federal University of the State of Rio de Janeiro in 1990, an M.Sc. degree in tropical medicine from the Oswaldo Cruz Foundation (Fiocruz) in 1990, and a Ph.D. degree in parasite biology from Fiocruz in 1997. He is currently a senior researcher at the Evandro Chagas Clinical Research Institute (IPEC/Fiocruz), coordinator of the Laboratory of Leishmaniasis Surveillance at IPEC/Fiocruz, coordinator of the Postgraduate Program in Clinical Research in Infectious Diseases of IPEC/Fiocruz, Level 2 researcher of the National Council of Scientific and Technological Development (CNPq), leader of the Parasitic Diseases (CNPq) research group, and a “Scientist of Our State” from the Foundation for Research of Rio de Janeiro (FAPERJ). He has experience in the study of infectious and parasitic diseases, mainly the clinical, diagnostic, treatment, and epidemiological aspects of sporotrichosis and leishmaniasis.